Plain-English translation of NCT07185022 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Stroke research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing whether rhTNK-tPA (Tenecteplase), a clot-dissolving medication, can help people recover better when injected directly into a blocked blood vessel in the brain during an acute stroke. Half of the participants will receive this medication along with standard stroke care, while the other half will receive standard care alone. The goal is to see whether this treatment helps people have better outcomes 90 days after their stroke.
Some strokes are caused by medium-sized blood vessel blockages that may not benefit as well from current standard treatments. Researchers want to know if delivering this medication directly to the clot using a special catheter procedure can improve recovery for these patients.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will be randomly assigned to one of two groups. One group receives standard emergency stroke treatment only, while the other group receives standard treatment plus the clot-dissolving medication injected into the blocked vessel using a catheter. The procedure takes place during the emergency treatment window (within 24–72 hours of symptom onset). You will then be followed for 90 days after your stroke, with assessments to measure your recovery and how well you are able to perform daily activities.
AI-generated summary from trial data · Aug 15, 2026 · Not medical advice
China